News

Results from both studies were presented today at the 2015 Gastrointestinal Cancers Symposium in San Francisco, Calif. VT-122 is a novel, chrono-modulated combination of the non-selective beta-adrenergic receptor

The data, presented at the 2015 Gastrointestinal Cancers Symposium in San Francisco, Calif., point toward potential therapeutic options beyond standard-of-care immunomodulatory agents and pan-HER inhibitors for patients with

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that stimulates the secretion of insulin from the pancreas. Exenatide, a GLP-1 analog, is currently marketed in injectable form only, and

For the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic

As part of the deal, UCB will receive the world-wide exclusive license to develop and commercialize Neuropore’s new small molecule NPT200-11in all indications. NPT200-11 that targets pathogenic alpha-synuclein

ATB-346 targets the need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation. According to the company, safety concerns centered on the finding of significant

Of the total amount, $5.65m will be spent on Coldstream facility on the Research Park Campus of the University, while the remaining will be used to acquire the

The combination has been approved with or without ribavirin (RBV) for these patients, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver

NBI-77860 is a potent, selective non-peptide CRF receptor antagonist as showed in a range of in vitro/in vivo assays and human clinical trials. Blockade of CRF receptors at